<DOC>
	<DOCNO>NCT02547987</DOCNO>
	<brief_summary>The purpose study determine whether combination docetaxel carboplatin effective treatment patient triple negative breast cancer .</brief_summary>
	<brief_title>Neoadjuvant Carboplatin Docetaxel Triple Negative Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVE : To determine whether neoadjuvant docetaxel carboplatin increase pCR rate TNBC compare historical control . Pathologic complete response ( pCR ) define residual invasive breast cancer breast ipsilateral axillary lymph node ( ypT0-is ypN0 ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>All patient must 18 year age old . All patient must diagnose invasive breast cancer . Breast cancer must ERnegative , HER2 negative accord CAP/ASCO biomarkers test guideline . Tumors may PgR positive Allred score less 5 . Primary breast tumor size least 2 cm one dimension clinical radiographic exam . Patients multicentric breast cancer eligible lesion ERnegative HER2negative . In case , one lesion need identified index lesion follow clinical response . The index lesion must also lesion core biopsy obtain . Normal bone marrow organ function define : Leukocytes &gt; 3,000/mcL Absolute neutrophil count &gt; 1,200/mcl Platelets &gt; 100,000/mcl Serum bilirubin ≤ institutional 1.5 time ULN AST ( SGOT ) /ALT ( SGPT ) ≤ 1.5 time ULN Creatinine ≤ 1.5 ULN Women childbearing potential ( defined woman age 55 intact ovary uterus ) must agree use adequate contraception prior study entry duration study participation . They must also negative urine pregnancy test within 7 day start treatment . Ability understand willingness sign IRB approve write informed consent document follow study procedure include willingness undergo study biopsy . Any prior systemic therapy breast cancer within 5 year . A history malignancy ≤ 5 year previous exception basal cell squamous cell carcinoma skin treat local resection carcinoma situ cervix . Patients known bilateral invasive breast cancer . Patients contralateral situ breast carcinoma eligible . Inflammatory breast cancer . Patients confirm stage IV disease . Currently receive investigational agent . A history allergic reaction attribute compound similar chemical biologic composition docetaxel carboplatin . Known seropositive HIV , HCV , HBV . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . If patient otherwise deem good study candidate sole discretion principal investigator . Patient pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>triple negative</keyword>
	<keyword>TNBC</keyword>
	<keyword>triple negative breast cancer</keyword>
</DOC>